Braun et al., 2008 - Google Patents
HIV-1 capsid assembly inhibitor (CAI) peptide: structural preferences and delivery into human embryonic lung cells and lymphocytesBraun et al., 2008
View HTML- Document ID
- 9304991222252846692
- Author
- Braun K
- Frank M
- Pipkorn R
- Reed J
- Spring H
- Debus J
- Didinger B
- von der Lieth C
- Wiessler M
- Waldeck W
- Publication year
- Publication venue
- International journal of medical sciences
External Links
Snippet
The Human immunodeficiency virus 1 derived capsid assembly inhibitor peptide (HIV-1 CAI- peptide) is a promising lead candidate for anti-HIV drug development. Its drawback, however, is that it cannot permeate cells directly. Here we report the transport of the …
- 210000004027 cells 0 title abstract description 32
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Geyer et al. | Structure of the anchor-domain of myristoylated and non-myristoylated HIV-1 Nef protein | |
| US11390646B2 (en) | Structure-based peptide inhibitors of α-synuclein aggregation | |
| Saad et al. | Point mutations in the HIV-1 matrix protein turn off the myristyl switch | |
| Luca et al. | Peptide conformation and supramolecular organization in amylin fibrils: constraints from solid-state NMR | |
| Caffrey et al. | Three‐dimensional solution structure of the 44 kDa ectodomain of SIV gp41 | |
| Young | Mechanisms of the Hsp70 chaperone system | |
| Saidi Brikci-Nigassa et al. | Phosphorylation controls the interaction of the connexin43 C-terminal domain with tubulin and microtubules | |
| Morellet et al. | Helical structure determined by NMR of the HIV‐1 (345–392) Gag sequence, surrounding p2: Implications for particle assembly and RNA packaging | |
| Schärpf et al. | Antitermination in bacteriophage λ: The structure of the N36 peptide‐boxB RNA complex | |
| Okuda et al. | Extended string binding mode of the phosphorylated transactivation domain of tumor suppressor p53 | |
| Kowalski et al. | NMR solution structure of the isolated Apo Pin1 WW domain: Comparison to the x‐ray crystal structures of Pin1 | |
| Shuaib et al. | Scrutiny of the mechanism of small molecule inhibitor preventing conformational transition of amyloid-β42 monomer: insights from molecular dynamics simulations | |
| Lacy et al. | Molecular basis for the specificity of p27 toward cyclin-dependent kinases that regulate cell division | |
| Bosco et al. | Catalysis and binding of cyclophilin A with different HIV-1 capsid constructs | |
| Carotenuto et al. | Conformation− activity relationship of designed glycopeptides as synthetic probes for the detection of autoantibodies, biomarkers of multiple sclerosis | |
| Tzakos et al. | On the molecular basis of the recognition of angiotensin II (AII) NMR structure of AII in solution compared with the X‐ray structure of AII bound to the mAb Fab131 | |
| Wong et al. | Solution structure of a double mutant of the carboxy-terminal dimerization domain of the HIV-1 capsid protein | |
| Farina et al. | Binding mode of AIF (370–394) peptide to CypA: insights from NMR, label-free and molecular docking studies | |
| Iaccarino et al. | Structure-based design of small bicyclic peptide inhibitors of Cripto-1 activity | |
| Braun et al. | HIV-1 capsid assembly inhibitor (CAI) peptide: structural preferences and delivery into human embryonic lung cells and lymphocytes | |
| Stote et al. | Structure of the His44→ Ala single point mutant of the distal finger motif of HIV-1 nucleocapsid protein: a combined NMR, molecular dynamics simulation, and fluorescence study | |
| Mercurio et al. | Peptide Fragments of Odin‐Sam1: Conformational Analysis and Interaction Studies with EphA2‐Sam | |
| Engler et al. | Solution structure of human immunodeficiency virus type 1 Vpr (13–33) peptide in micelles | |
| Byrne et al. | A β-turn motif in the steroid hormone receptor’s ligand-binding domains interacts with the peptidyl-prolyl isomerase (PPIase) catalytic site of the immunophilin FKBP52 | |
| Bellot et al. | Structure of the third intracellular loop of the vasopressin V2 receptor and conformational changes upon binding to gC1qR |